Vatiquinone (PTC743)

Small molecule

Also known as EPI-743, PTC725

CRLnot approved

Evidence outlook · regulatory review

Friedreich Ataxia: FDA issued a complete response letter (2025-08-19)

FDA issues complete response letter for the vatiquinone NDA in Friedreich's ataxia. A complete response letter means the application was not approved as filed; the sponsor may resubmit. The event is listed under Regulatory events.

Latest reported trial: MOVE-FA (NCT04577352) · Phase 2/3 · missed primary endpoint · grade pending

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Friedreich Ataxia
NCT07681713 · PTC Therapeutics
2026-08-15 – 2029-03-15 · Friedreich's Ataxia
What this study did
NCT05515536 · PTC Therapeutics
2022-12-08 – 2027-12-31 · Friedreich Ataxia
What this study did
Other / comorbidity
NCT05218655 · PTC Therapeutics
2022-06-22 – 2025-04-15 · Inherited Mitochondrial Disease
What this study did
Phase 2/3 (2)
Friedreich Ataxia
Other / comorbidity
NCT04378075 · PTC Therapeutics
2020-09-28 – 2023-12-27 · Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
What this study did
Phase 2 (11)
Friedreich Ataxia
NCT05485987 · PTC Therapeutics
2022-10-12 – 2024-08-29 · Friedreich Ataxia
What this study did
NCT01962363 · University of South Florida
2013-10 – 2016-06 · Friedreich's Ataxia
What this study did
NCT01728064 · PTC Therapeutics
2012-12-31 – 2016-02-29 · Friedreich's Ataxia
What this study did
Other / comorbidity
NCT02352896 · PTC Therapeutics
2014-01-31 – 2023-10-30 · Leigh Syndrome
What this study did
NCT01793090 · Bambino Gesù Hospital and Research Institute
2013-01 – 2017-02 · Methylmalonic Aciduria and Homocystinuria,Cblc Type, Genetic Disease, Retinopathy
What this study did
NCT01923584 · University of South Florida
2013-09 – 2016-06 · Parkinson's Disease
What this study did
NCT02104336 · Edison Pharmaceuticals Inc
2014-08-31 – 2016-02-29 · Pearson Syndrome
What this study did
NCT02257983 · Edison Pharmaceuticals Inc
2014-10-31 – 2016-02-29 · Noise-induced Hearing Loss
What this study did
NCT02226458 · Edison Pharmaceuticals Inc
2014-10-31 – 2016-01-31 · Autism Spectrum Disorder
What this study did
NCT01721733 · PTC Therapeutics
2012-10-31 – 2015-05-31 · Leigh Syndrome
What this study did
NCT01822249 · Edison Pharmaceuticals Inc
2013-01 – 2014-01 · Rett Syndrome
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01642056 · National Human Genome Research Institute (NHGRI)
2012-09-01 – 2019-09-24 · Mitochondrial Disease, Neurology, Myopathy
What this study did
Phase 1 (1)
Other / comorbidity
NCT01719523 · Yale University
2012-10 – 2013-10 · Tourette Syndrome
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Vatiquinone (PTC743) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 3Friedreich AtaxiaActive not recruiting
Est. primary completion 2027-12-31 · NCT05515536 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 3Friedreich AtaxiaNot yet recruiting
Est. primary completion 2029-03-15 · NCT07681713 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 August 2025Complete response letterFDA issues complete response letter for the vatiquinone NDA in Friedreich's ataxia
US, FDA · PTC Therapeutics · Source ↗
February 2025Filing acceptedFDA accepts the vatiquinone NDA
US, FDA · Source ↗
December 2024Filing submittedVatiquinone NDA submitted to the FDA
US, FDA · Source ↗
October 2024Topline resultLong-term extension studies met their prespecified endpoint